Abstract: The Hippo signaling pathway and its downstream effectors, YAP/TAZ and TEAD transcription factors, play a critical role in driving tumor proliferation, survival, and resistance to targeted therapies. GNE-7883 is a novel, potent, and reversible small-molecule inhibitor that allosterically targets the lipid pocket of all four human TEAD paralogs (pan-TEAD). By binding to this pocket, GNE-7883 disrupts the protein-protein interaction between YAP/TAZ and TEADs, leading to a specific reduction in chromatin accessibility at TEAD motifs and the suppression of YAP/TAZ target gene transcription. Preclinical studies demonstrate that GNE-7883 exhibits strong antiproliferative activity in YAP/TAZ-dependent cancer models and shows robust in vivo efficacy. Furthermore, GNE-7883 effectively overcomes both intrinsic and acquired resistance to KRAS G12C inhibitors, highlighting its broad therapeutic potential in precision oncology.
1. Introduction
The Hippo pathway is an evolutionarily conserved signaling network that regulates essential cellular processes, including organ size, cell proliferation, and apoptosis [2]. The terminal effectors of this pathway are the transcriptional coactivators YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), which interact with the TEAD family of transcription factors (TEAD1-4) to drive the expression of growth-promoting genes [1][2]. Dysregulation of the Hippo pathway—often through genetic alterations such as NF2 loss or YAP amplification—is a prominent driver of human cancers and a robust mechanism of resistance to various targeted therapies, including KRAS G12C inhibitors [1]. Because YAP and TAZ lack apparent druggable pockets, therapeutic efforts have shifted toward targeting the TEAD transcription factors [1]. GNE-7883 has recently emerged as a potent, reversible, allosteric pan-TEAD inhibitor capable of blocking the oncogenic YAP/TAZ-TEAD interaction, presenting a promising strategy for pharmacological modulation of transcriptional regulation in oncology [1][2].
2. Pharmacological Activity
GNE-7883 demonstrates potent pharmacological activity across a variety of YAP/TAZ-dependent cancer models. In vitro, it strongly inhibits the proliferation of YAP-amplified OVCAR-8 cells (EC50 = 115 nM) and NF2-null NCI-H226 cells (EC50 = 333 nM) [2], as well as HCC1576 and multiple NF2-null mesothelioma cell lines [1]. The compound's antiproliferative effect correlates significantly with baseline YAP/TAZ transcriptional target scores across diverse cancer cell lines [1].
In vivo, subcutaneous administration of GNE-7883 at 250 mg/kg achieved strong antitumor efficacy. It induced tumor stasis in the NCI-H226 mesothelioma xenograft model (102% tumor growth inhibition) and drove tumor regression in the MSTO-211H model, all while maintaining a favorable tolerability profile with no treatment-associated body weight loss [1][2]. Beyond single-agent efficacy, GNE-7883 has proven highly effective in combination therapies. It synergizes with the KRAS G12C inhibitor sotorasib, successfully overcoming both intrinsic and acquired resistance in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) xenograft and patient-derived xenograft (PDX) models [1].
3. Molecular Mechanism of Action
GNE-7883 functions as an allosteric inhibitor that binds to the central lipophilic (palmitate) pocket of TEAD transcription factors [1][2]. While some earlier TEAD binders block autopalmitoylation without disrupting the YAP/TAZ-TEAD complex, GNE-7883 actively displaces YAP and TAZ from all four human TEAD paralogs [1]. Structurally, GNE-7883 binds between the first and second TEAD helices that form the YAP-binding site 2. By displacing the Gln410 residue within the lipid pocket, the compound alters the conformational landscape of site 2, creating tension that allosterically blocks the protein-protein interaction (PPI) between YAP/TAZ and TEAD [1].
At the level of transcriptional regulation, GNE-7883 does not alter the nuclear or cytosolic localization of YAP, TAZ, or TEAD. Instead, it specifically remodels chromatin by decreasing accessibility predominantly at distal enhancer regions enriched with TEAD motifs. This leads to a prominent decrease in the transcription of well-known YAP/TAZ target genes, such as ANKRD1 and CCN1 (CYR61), thereby shutting down the pro-tumorigenic transcriptional program [1].
4. Structure-Activity Relationship (SAR)
GNE-7883 was developed from a pyrazolopyrimidinone-based small-molecule inhibitor series [1]. Early optimization efforts focused on improving pan-TEAD potency by targeting Ser345 (in TEAD2), a conserved hydroxyl motif located in an unoccupied hydrophilic region near the entrance of the ligand-binding pocket across all TEAD paralogs. The introduction of polar groups, specifically a pyrazine ring, enabled the formation of a productive hydrogen bond with the Ser345 side chain [1].
Further refinement involved replacing a cyanopyrrolidine group with a 4-fluoromethyl azetidine to balance overall polarity. The critical breakthrough leading to GNE-7883 was the addition of a methyl group to the pyrazine heterocycle. This modification resulted in a substantial biochemical potency gain against TEAD4 and increased cellular antiproliferative effects. Co-crystal structures of GNE-7883 bound to TEAD2 confirmed that the methylpyrazine group successfully interacts with Ser345 and expands a water-mediated interaction network to include Ser377 and the main-chain carbonyls of Leu345 and Val329 [1].
5. Current Limitations
A primary limitation of GNE-7883 is its suboptimal pharmacokinetic profile. The compound exhibits low oral bioavailability (approximately 6% at a 25 mg/kg dose), which necessitates subcutaneous administration in rodent models to achieve sufficient exposure for in vivo efficacy [1]. Additionally, the broader preclinical evaluation of YAP/TAZ inhibitors has historically been hindered by a reliance on xenograft cell line models, due to a lack of robust patient-derived xenograft (PDX) models that are specifically driven by genetic alterations in the Hippo pathway [1].
6. Future Perspectives
GNE-7883 represents a highly attractive pharmacological tool to further probe Hippo pathway biology in cancer and to evaluate the therapeutic impact of allosteric YAP1-TEAD complex disruption across various genetic backgrounds [2]. The successful demonstration of GNE-7883's ability to suppress adaptive and intrinsic YAP/TAZ activation in the context of KRAS G12C inhibitor resistance provides a strong proof-of-concept. These findings offer a compelling rationale for advancing pan-TEAD inhibitors into human clinical trials, which will be essential to fully realize the potential of this molecular class in precision oncology and in overcoming targeted therapy resistance [1].
